Escitalopram in the Treatment of Postpartum Depression
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This will be an 8-week, open-label trial evaluating the efficacy of escitalopram as
monotherapy in the treatment of patients with postpartum depression (PPD). The acute phase of
the study will consist of an 8 week treatment phase. Treatment of eligible participants will
be initiated at a dose of 10mg/day which will be adjusted by the study clinician based on the
presence of depressive symptoms and side effects up to a maximum of 20mg/day.
Study objectives are:
1. to investigate the efficacy of escitalopram in the treatment of PPD.
2. to assess the effects of escitalopram on patients quality of life.